Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs. https://t.co/R0r7ViaxGP ...

Novo Nordisk is out with results this morning now lowering its fullear profit uh and revenue uh forecast. Meanwhile, uh the company it's it's getting very interesting in terms uh of uh this possible uh bidding war uh that uh that we are seeing as we move that up a little bit please. That's what this means.Yeah, there you go. Keep going. Keep going. Keep going.Joining us now, Novo Nordis CEO Mike Dudstar. It's good to have you on. Uh can we talk uh about how much this is uh cherished this company met very sm ...

Key Products & Market Performance - Tzepide and Mjaro (Zepbound) achieved market leadership in the US for both diabetes and obesity, driven by strong international performance [2] - Mangaro rollout in China, Brazil, and India indicates strong global demand [3] - Oral pill orforglipron is completing Phase 3 program with submission in Q4, aiming for broad global rollout [4][6] Pipeline & Clinical Trials - Oral pill offers a less intrusive alternative to injections, potentially appealing to those reaching their weight target [8] - Retatrutide, a triple-acting agent, shows promise for even greater weight loss than Zepbound or Mounjaro, with initial study focused on knee pain [10] - Studies are exploring the effects of weight loss drugs on inflammation, chronic knee pain, and addictive properties in the brain [11][12] Strategic Outlook - The company anticipates continued FDA approvals, supported by user fees, despite potential government shutdowns [7] - The company has built a head inventory to introduce orforglipron around the world [8] - The company is exploring additional indications beyond weight loss, such as knee pain and back pain, targeting a larger patient population [9][10]

One of the sort of miracle drugs right now that everyone's talking about are GLP-1s and how they have so many applications. Obviously, they're very expensive. The last administration had talked about opening them up to people.Obviously, it's a big upfront cost, but ultimately because it makes people healthier down the line, it might pay off. What are your thoughts on making GLP1s available for weight loss in Medicare. Can we afford it or can we afford not to do it.>> Uh, it's the only question I'm going to ...

this is propaganda btwmounjaro 100% works (it's the 2nd version of ozempic, way better)it's *insane* how well it worksI lost 50-60 lbs in 1 year by basically changing nothing elseit also helps you quit nicotine (i quit with 0 relapse)it should be in the public waterAutism Capital 🧩 (@AutismCapital):🚨 TRUMP: “I call Ozempic the fat drug. Sometimes it works for people, but the ones I’ve seen it hasn’t worked that well. I have friends that are fat and they said ‘I lost some weight,’ I said ‘You don’t look it t ...

Core Insights - An experimental GLP-1 pill named orforglipron has shown significant weight loss results in clinical trials without requiring weekly injections [1] Group 1 - The clinical trial results indicate that orforglipron promotes substantial weight loss [1]

Product & Technology - Signos leverages AI and continuous glucose monitoring (CGM) via a wearable biosensor to provide real-time metabolic insights for weight management [2][3] - The device, featuring a micro-needle, is worn for 15 days and provides data accessible via a phone app [3][4] - Signos aims to predict weight-related outcomes by providing personalized recommendations (e.g, suggesting a walk after a meal) based on glucose levels [5] - Signos integrates with other wearable devices like Apple Watch, complementing their data with AI-driven predictions [13][14] Market & Competition - Signos positions itself as a complementary solution to GLP-1 drugs, targeting a broader audience beyond those with obesity, focusing on weight loss and maintenance [7] - The company aims to establish metabolism as the "fifth vital sign," promoting continuous monitoring outside of clinical settings [8] - The FDA clearance covers the device's accuracy in measuring glucose levels for weight management, including weight loss and maintenance [9] Business Model & Financials - The service costs $129 per month and is FSA/HSA eligible [6] - Signos is actively pursuing partnerships with insurers for reimbursement coverage [6] Clinical Benefits - Stabilizing glucose levels can lead to improved sleep quality, as demonstrated by a user experience of tripled deep sleep duration [11][12]

Or maybe he’s in his 50s and he was advised he can’t take heroic doses of steroids anymore if he wants to live a long life.Gabe Pluguez | Default Kings (@Gabepluguez):Everyone's shocked about The Rock's massive weight loss…But he recently sat down with Dr. Mark Hyman & broke down what's REALLY going on with his health.What he revealed will make you rethink going to the doctor…Here are my top 8 takeaways: https://t.co/yNlg5VGdDK ...

Switching gears, Eli Lily surging almost 6%. It led the S&P 500 today. Their obesity pill cleared yet another late stage trial.Patients with type 2 diabetes and obesity losing an average 10 a.5% of their body weight after 72 weeks is on the highest dose. For more on what may come next, city research managing director Jeff Meechum joining us now. Jeff, great to have you on the show.What did these results mean for Lily. >> Awesome. Thanks for having me, Brian.Um, yes. So, the results here are derisking from t ...

Eli Lily shares. Let's have a look at those after that news that we just uh reported that the pharma giant released more data on its obesity pill. Patients with obesity and diabetes lost about 10.5% of their body weight.The data clears the way for Lily to seek regulatory approval. Shares are up 1.7% when they got some data on this a month or so ago or just under a month ago they did fall. Let's get clarity on which bit of the data outweighs the other.Tim Anderson, Bank of America Security senior pharma anal ...